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Abstract	
Objective	
Ovarian cancers comprise several histologically distinct tumour groups with widely different 
prognosis. We aimed to describe the worldwide distribution of ovarian cancer histology and to 
understand what role this may play in international variation in survival. 
Methods	
The CONCORD programme is the largest population-based study of global trends in cancer 
survival. Data on 681,759 women diagnosed during 1995–2009 with cancer of the ovary, fallopian 
tube, peritoneum and retroperitonum in 51 countries were included. We categorised ovarian 
tumours into six histological groups, and explored the worldwide distribution of histology. 
Results	
During 2005–2009, type II epithelial tumours were the most common. The proportion was much 
higher in Oceania (73.1%), North America (73.0%) and Europe (72.6%) than in Central and South 
America (65.7%) and Asia (56.1%). By contrast, type I epithelial tumours were more common in 
Asia (32.5%), compared with only 19.4% in North America. From 1995 to 2009, the proportion of 
type II epithelial tumours increased from 68.6% to 71.1%, while the proportion of type I epithelial 
tumours fell from 23.8% to 21.2%. The proportions of germ cell tumours, sex cord-stromal 
tumours, other specific non-epithelial tumours and tumours of non-specific morphology all 
remained stable over time. 
Conclusions	
The distribution of ovarian cancer histology varies widely worldwide. Type I epithelial, germ cell 
and sex cord-stromal tumours are generally associated with higher survival than type II tumours, so 
the proportion of these tumours may influence survival estimates for all ovarian cancers combined. 
The distribution of histological groups should be considered when comparing survival between 
countries and regions. 
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1.	Introduction	
Of all gynaecological malignancies, ovarian cancer causes the second highest number of deaths 
worldwide, accounting for over 151,000 deaths annually [1]. Symptoms, such as persistent 
abdominal pain, bloating or decreased appetite, are vague [2]. Most women present with advanced-
stage disease [3] and five-year survival is around 30–40% [4]. Ovarian cancer is not a single disease 
[2], [5], but includes several histological subtypes that have widely different prognosis [6], [7]. 
Ovarian cancer has been divided into epithelial and non-epithelial groups for many years, but recent 
work has enabled finer subdivision of epithelial ovarian cancers into different groups according to a 
combination of morphological and clinical characteristics [6], [7], [8], [9], [10]. Type I epithelial 
tumours include low-grade serous, endometrioid, clear cell, mucinous and transitional cell 
(Brenner) carcinomas. They often present at an early stage, may arise from borderline ovarian 
tumours or endometriosis and typically have a good prognosis. Type II epithelial tumours comprise 
high-grade serous carcinoma, undifferentiated carcinomas and malignant mixed mesodermal 
tumours. They account for around 75% of epithelial ovarian cancers, typically present at an 
advanced stage and have a poor prognosis [6], [7], [9]. Each histological group has distinct 
molecular pathways that influence chemosensitivity, the pattern of metastasis and the probability of 
survival [9], [11]. 
The pathogenesis of ovarian cancer is not fully understood. Recent evidence, particularly from 
prophylactic oophorectomies in women at a high risk of ovarian cancer because of BRCA gene 
mutations, suggests that the most common subtype, high-grade serous carcinoma, originates either 
in the fallopian tube or on the surface of the ovary. Therefore, fallopian tube carcinoma has more 
recently been included in a broader definition of ovarian cancer [7]. Primary peritoneal carcinoma is 
also managed in the same way as advanced-stage epithelial ovarian cancer [6], [12]. 
International comparisons of cancer incidence, mortality and survival are crucial to inform and plan 
health policy and cancer control programmes. Low survival has been a stimulus for cancer plans 
and strategies in many countries, such as the United Kingdom and Denmark [3]. Comparisons of 
lung cancer survival have routinely been divided into small-cell and non-small cell subtypes due to 
the different prognosis and behaviour of these tumours. Ovarian cancer is arguably an even more 
heterogeneous disease than lung cancer, and histology should thus be considered in the 
interpretation of international variation in ovarian cancer survival. Type I epithelial tumours are 
generally associated with higher survival than type II tumours, so the proportion of type I epithelial 
tumours may influence survival estimates for all ovarian cancers combined. Differences in the 
distribution of histology may thus contribute to international variations in survival from all ovarian 
cancers combined, in addition to international differences in stage at diagnosis and treatment. 
The CONCORD-2 study on the global surveillance of cancer survival has shown the extent to 
which ovarian cancer survival varies worldwide [4]. However, it remains unclear how much of the 
variation in ovarian cancer survival could be attributed to international variation in the histological 
groups, in particular the distribution of type I and type II epithelial tumours. Using population-based 
data from the CONCORD-2 study, we have examined the international distribution of ovarian 
cancer histology. Our aims were to describe the worldwide variation of ovarian cancer histological 
groups, and then to discuss whether this variation may influence international comparisons of 
population-based cancer survival. 
2.	Methods	
The CONCORD-2 study [4] collected information for over 779,000 adult women (aged 15–
99 years) in 61 countries who were diagnosed during the 15-year period 1995 to 2009 with a cancer 
of the ovary, fallopian tube, uterine ligaments and adnexa, other specific and unspecified female 
genital organs, peritoneum or retroperitoneum (International Classification of Diseases for 
Oncology, 3rd edition (ICD-O-3) topography codes C56.9, C57.0–C57.4, C57.7–C57.9, C48.0–
C48.2) [13]. The CONCORD-2 protocol, the ethical approvals and the quality control procedures 
have been described [4]. 
We defined six histological groups based on previous literature [14] and clinical advice [Table 1]. 
Clear cell, endometrioid, mucinous, squamous and transitional cell carcinomas were grouped as 
type I epithelial tumours, and serous carcinoma, mixed epithelial and stromal carcinoma and 
undifferentiated and other epithelial carcinoma were grouped as type II epithelial tumours. 
Table 1. Ovarian cancer histological groups and subtypesa. 
Histological group  Histological subtype  ICD‐O‐3 morphology code 
Type I epithelial 
Clear cell carcinoma  8005, 8310, 8443, 9110
Endometrioid carcinomab  8380, 8382–8383, 8560, 8570
Mucinous carcinoma  8470–8471, 8480–8482, 8490
Squamous carcinoma  8051–8084
Transitional cell or Brenner 
carcinoma  8120–8131, 9000 
Type II epithelial 
Serous carcinomac  8050, 8441, 8450, 8460–8461
Mixed epithelial‐stromal 
carcinoma  8313, 8323, 8381, 8930–8991, 9010–9030 
Undifferentiated or other 
epithelial 
8010–8015, 8020–8046, 8090–8110, 8140–8231, 8246–8300, 8311–8312, 8314–8322, 8324–8325, 
8336–8337, 8341–8375, 8384–8440, 8452–8454, 8500–8551, 8561–8562, 8571–8589 
Germ cell  Germ cell  8240–8245, 8330–8335, 8340, 9060–9105, 9380–9523
Sex cord‐stromal  Sex cord‐stromal 8590–8671, 8810
Other specific non‐
epithelial 
Other specific non‐
epithelial  8680–8806, 8811–8921, 9040–9055, 9120–9373, 9530–9589 
Non‐specific  Non‐specific  8000–8004
aNo information on grade was available, therefore all endometrioid tumours were classified as type I epithelial. 
bNo information on grade was available, therefore all serous tumours were classified as type II epithelial. 
cBorderline tumours (ICD‐O‐3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) were excluded from the analysis of distribution of histological 
subtypes (see text). 
Ovarian cystadenomas were reclassified in ICD-O-3 from invasive (behaviour code of 3) to 
borderline (behaviour code of 0 or 1), but some registries coded tumours of borderline behaviour as 
invasive despite the changes from ICD-O-2 to ICD-O-3. Borderline tumours were excluded from 
the analysis of the distribution. Morphology codes for haematological malignancies were also 
excluded from analysis. 
Data were available for 793,098 women for analysis [supplementary Fig. 1]. Women diagnosed 
with borderline tumours, haematological malignancies or whose records included invalid ICD-O-3 
codes (codes not included in either ICD-O-2 or ICD-O-3) were excluded (n = 13,073). Of the 
remaining 780,025 women, 90.6% (706,807) had tumours that were coded by the registry as having 
been morphologically verified, while 7.5% (58,682) were coded as not morphologically verified 
and 1.9% (14,536) were coded as unknown whether morphologically verified or not. For tumours 
coded as morphologically verified, 705,997 (99.9%) had a valid ICD-O-3 morphology code, but no 
morphology code was available for 810 (0.1%), and these tumours were excluded. Tumours coded 
as not morphologically verified were primarily tumours with missing morphology (30,287, 51.6% 
of non-morphologically verified tumours); these tumours were excluded. We excluded a further 
18,200 non-morphologically verified tumours with non-specific morphology. We included the 
remaining 10,195 tumours that had been coded as not having been morphologically verified, 
because a specific ICD-O-3 morphology code was nevertheless available, implying that 
morphological verification had in fact been performed. Tumours for which it was unknown whether 
morphological verification had been performed or not were evenly distributed across specific 
(n = 5017), non-specific (n = 4798) and missing morphology (n = 4721). Of these tumours, we 
excluded tumours with non-specific and missing morphology. We included the remaining 5017 
tumours coded as unknown whether morphologically verified, because a specific morphology was 
also recorded, again implying that morphological verification had been completed. 
In total, 721,209 women (98.3% with specific ICD-O-3 morphology codes and 1.7% with non-
specific codes) were available for analysis after the first round of exclusions. 
We examined the distribution of ovarian cancer histology for all countries in any calendar period 
(1995–1999, 2000–2004 and 2005–2009) for which data were available for at least 100 women. 
Registries from which the survival estimates in the main CONCORD-2 analysis were considered 
less reliable [4] were also excluded, because the results from this analysis will be used to inform the 
results of survival analyses of ovarian cancer by histological group. Survival estimates were flagged 
as less reliable if a higher than usual proportion of patients was excluded from analyses because the 
cancer was registered only through a death certificate, or the date of last vital status was not known. 
The focus of this analysis was the distribution of specific histological groups, so women diagnosed 
in Sweden had to be excluded, because 97.5% of tumours were coded by the registry as 
undifferentiated or other epithelial carcinoma or as non-specific morphology (ICD-O-3 codes 8000–
8004). After all exclusions, 681,759 women (86.0% of the total number for whose data were 
available for analysis) were included in the analysis of the histological distribution (192,080 in 
1995–1999; 240,397 in 2000–2004; 249,282 in 2005–2009) [supplementary Table 1]. 
3.	Results	
Type II epithelial tumours were the most common histology worldwide (476,461; 69.9%), followed 
by type I epithelial (152,874; 22.4%) [Fig. 1]. Germ cell, sex cord-stromal, other specific non-
epithelial and non-specific tumours were all rare and they only comprised 8% of tumours 
worldwide; the distribution of these groups remained relatively stable over the 15-year period 1995 
to 2009. The proportion of type II epithelial tumours increased slightly from 68.6% to 71.1% from 
1995 to 2009, and there was a corresponding decrease in type I epithelial tumours (from 23.8% to 
21.2%: supplementary Table 1). 
During 2005–2009, type II epithelial was the most common group in all continents, although the 
proportion was much higher in Oceania (73.1%), North America (73.0%) and Europe (72.6%) than 
in Central and South America (65.7%) and Asia (56.1%) [Fig. 2 and Table 2]. The range at the 
national level, however, was much wider. The highest proportion of type II tumours was in Latvia 
(78.9%), with the lowest proportion in Thailand (40.4%) [supplementary Table 4]. There was little 
between-country variation in the proportion of type II tumours in Central and South America, North 
America and Oceania. However, the proportion varied widely in Asia, where the proportion of type 
II tumours was lower than that of type I epithelial tumours in Hong Kong and Thailand [Fig. 3]. 
There was also variation in the proportion of type II tumours in Europe, where they accounted for 
over 70% of tumours in 15 countries, 60% in 11 countries and only 50.2% in Russia 
[supplementary Table 4]. The distribution of type II epithelial subtypes (serous, undifferentiated and 
other epithelial and mixed epithelial and stromal carcinoma) also varied by country, continent and 
calendar period. 
Table 2. Distribution of histological groups by continent and calendar period of diagnosisa. 
 Total no. 
Type I epithelialb Type II epithelialc Germ cell Sex cord-stromal Other specific non-epithelial Non-specificd 
No. % No. % No. % No. % No. % No. % 
America (Central and South) 
1995–99 1113 220 19.8 720 64.7 50 4.5 30 2.7 61 5.5 32 2.9 
2000–04 3278 587 17.9 2209 67.4 124 3.8 90 2.7 131 4.0 137 4.2 
2005–09 2699 570 21.1 1772 65.7 106 3.9 74 2.7 92 3.4 85 3.1 
America (North) 
1995–99 87,459 20,783 23.8 60,433 69.1 1591 1.8 1360 1.6 2413 2.8 879 1.0 
2000–04 101,774 22,007 21.6 72,480 71.2 1907 1.9 1454 1.4 2734 2.7 1192 1.2 
2005–09 106,898 20,710 19.4 78,075 73.0 2167 2.0 1656 1.5 3079 2.9 1211 1.1 
Asia 
1995–99 12,920 4324 33.5 6775 52.4 770 6.0 268 2.1 361 2.8 422 3.3 
2000–04 19,312 6588 34.1 10,242 53.0 940 4.9 422 2.2 609 3.2 511 2.6 
2005–09 24,533 7979 32.5 13,775 56.1 1042 4.2 497 2.0 667 2.7 573 2.3 
Europe 
1995–99 84,056 18,887 22.5 59,229 70.5 1149 1.4 1633 1.9 1897 2.3 1261 1.5 
2000–04 108,891 23,625 21.7 77,376 71.1 1537 1.4 1965 1.8 2526 2.3 1862 1.7 
2005–09 108,766 22,313 20.5 78,957 72.6 1453 1.3 1784 1.6 2491 2.3 1768 1.6 
Oceania 
1995–99 6532 1556 23.8 4546 69.6 133 2.0 89 1.4 156 2.4 52 0.8 
2000–04 7142 1466 20.5 5201 72.8 180 2.5 66 0.9 182 2.5 47 0.7 
2005–09 6386 1259 19.7 4671 73.1 160 2.5 56 0.9 170 2.7 70 1.1 
aBorderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) were excluded from the analysis of distribution of histological 
subtypes (see text). 
bNo information on grade was available, therefore all endometrioid tumours were classified as type I epithelial. 
cNo information on grade was available, therefore all serous tumours were classified as type II epithelial. 
dMorphologically verified tumours with ICD-O-3 morphology codes 8000–8004. Only countries with at least 100 women in any given time period 
were included. All tumours with a specific ICD-O-3 morphology code were included. 
Type I epithelial tumours were the second most common group for all continents during 2005–
2009, but the range was wide. The highest proportion was seen in Asia (32.5%), while North 
America showed the lowest proportion (19.4%) [Table 2]. The proportion was similar in all 
countries in Central and South America, North America and Oceania [supplementary Table 4]. In 
Europe, however, there was wider variation, the proportion ranging from 11.3% in Latvia to 28.7% 
in Finland [supplementary Table 4]. The variation was even wider for countries in Asia, with the 
lowest proportion in Israel (12.8%) and the highest in Hong Kong (51.7%) [Fig. 3]. The distribution 
of specific type I epithelial subtypes (clear cell, endometrioid, mucinous, squamous and transitional 
cell (Brenner)) also varied over time and differed by country and continent [supplementary Table 2, 
supplementary Table 3 and supplementary Table 5]. 
Germ cell tumours were uncommon everywhere; the proportion in Asia (4.2%) was the highest in 
any continent, over three times the proportion seen in Europe (1.3%) [Table 2]. The proportion was 
similar for all countries in Europe (1.3%), North America (2.0%) and Oceania (2.5%). However, 
there was wide variation between countries in Central and South America and Asia. In Central and 
South America, the lowest proportion (1.6%) was seen in Cuba, and the highest (7.8%) in Ecuador 
[supplementary Table 4]. Among Asian countries, the variation was wider, with the lowest 
proportion in Cyprus (0.9%), and the highest in Jordan (8.1%) [Fig. 3]. 
Sex cord-stromal tumours were even more uncommon than germ cell tumours. The proportion also 
varied widely between countries in Asia, Central and South America and Europe. The proportion 
was similar for all countries in North America (1.5%) and Oceania (0.9%) [Table 2, supplementary 
Table 4]. The widest between-country variation was seen in Europe, with only 0.3% of tumours 
diagnosed as sex cord-stromal in Denmark, but 11.4% in Russia [supplementary Table 4]. In 
Central and South America, the proportion ranged from 1.6% in Brazil and Puerto Rico to 4.5% in 
Cuba. The lowest proportion in Asia was in Israel (0.6%), while the highest proportion was in 
Jordan (4.7%) [Fig. 3]. 
The highest proportion of other specific non-epithelial tumours (3.4%) was in Central and South 
America. The proportion was generally less than 5% in all countries, and between-country variation 
within each continent was small. The widest variation in the proportions was seen in Asia (0.5% in 
Indonesia and 5.8% in Cyprus) and Europe (0.6% in Croatia and 5.9% in Iceland) [supplementary 
Table 4]. 
Non-specific tumours generally accounted for 3% or less of ovarian tumours in all countries. The 
highest proportion was recorded in Russia (17.7%), much higher than the next highest proportion 
(Malta, 6.3%). The lowest proportions of non-specific tumours were seen in the Netherlands and 
Slovenia (0.1%) [supplementary Table 4]. 
4.	Discussion	
This is the largest study of the distribution of ovarian cancer histology. It is based on individual 
patient records from 218 population-based cancer registries in 51 countries. Data were available for 
681,759 women, including 249,282 diagnosed between 2005 and 2009. Type II epithelial tumours 
were the most common histological group in each continent, but the distribution of histological 
groups varied greatly worldwide. The distribution was similar in Europe, North America and 
Oceania, while there was a much higher proportion of type I epithelial tumours seen in Asia. 
Previous studies of the histological subtypes of ovarian cancer have focused on epithelial tumours, 
and they have generally been limited to a small number of countries. One meta-analysis included 
data for 98,099 women from 41 studies published between 1992 and 2012, only 12 of which used 
data from population-based registries [15]. The results were similar to those found in this study, 
with type II epithelial tumours more common than type I epithelial tumours. The distribution of 
subtypes between countries included in the meta-analysis was heterogeneous. 
Some of the variations in the distribution of ovarian cancer histology may be explained by ethnicity. 
A higher proportion of type II epithelial tumours diagnosed between 2005 and 2009 was reported in 
Israel (77.8%) than in most other countries. This may be attributable to the fact that a high 
percentage of the population in Israel is of Jewish ancestry, in whom BRCA1 and BRCA2 gene 
mutations are more common than in other populations. Serous tumours, which are classified as type 
II epithelial, are the most common histological subtype among women with BRCA1 and BRCA2 
mutations [16]. 
The proportions of type I and type II epithelial tumours were markedly different between the US 
and Japan. In Japan, 41.3% of tumours were type I epithelial and 47.5% were type II epithelial, 
compared to 19.0% and 73.2% in the US [supplementary Table 4]. The lower proportion of serous 
tumours in Japan and other East Asian countries is due in part to the higher proportion of clear cell 
cancers [supplementary Table 5]. These differences are most probably due to the higher incidence 
of endometriosis, a potential pre-cursor of clear cell and endometrioid tumours [17], in East Asian 
women [18]. 
The proportion of mucinous tumours varied, ranging from over 10% in most Asian countries to 5–
6% in most North American, European and Oceanian countries. The higher proportion in Japan is 
not clearly explained. Many tumours classified as mucinous may in fact be metastatic to the ovary 
from the gastrointestinal tract, including the stomach, which has a high incidence in Asia [19], [20]. 
The reduction in the worldwide proportion of mucinous ovarian cancer from 9.2% to 6.8% from 
1995 to 1999 and 2005 to 2009 [supplementary Table 5] may be partially attributable to more 
accurate immunohistochemical and imaging assessment, which allows for the exclusion of primary 
mucinous tumours from a different primary site, particularly those of the gastrointestinal tract. It 
can otherwise be difficult to differentiate a true primary mucinous ovarian cancer from mucinous 
tumours that are metastatic to the ovary [21]. 
Germ cell and sex cord-stromal tumours of the ovary should be considered separately in survival 
analysis, because they typically have higher survival than epithelial ovarian cancers. The proportion 
of germ cell tumours was less than 3% in most countries, but in some Asian and Central and South 
American countries, the proportions were much higher (5–8%). These differences are important, 
because the incidence of germ cell tumours is highest among young women and survival is usually 
very high, even with the tumour is diagnosed at an advanced stage, if optimal treatment is 
achievable [22]. The higher proportion of germ cell tumours in Asia and Central and South America 
may therefore be due to the younger age profile of populations in these regions. The proportion of 
sex cord-stromal tumours was less than 2% in most countries, but much higher in some European 
countries. These differences are also important in the comparison of survival from ovarian cancers 
combined, because survival is much higher for sex cord-stromal tumours than for epithelial ovarian 
cancers [23]. 
Variation in the distribution of histological groups of ovarian cancer may impact international 
comparisons of survival from all ovarian cancers combined if countries with more favourable 
histological distributions, where more tumours are classified as type I epithelial, germ cell or sex 
cord-stromal, are compared to survival in countries with higher proportions of type II epithelial 
tumours. In the main CONCORD-2 analysis [4], age-standardised 5-year survival from all ovarian 
tumours combined was higher in some East Asian countries than in Europe, North America and 
Oceania. In Hong Kong, 5-year survival was 52.9% for women diagnosed from 2005 to 2009, much 
higher than the highest level of survival in Europe (Finland: 44.9%), North America (US: 40.9%) 
and Oceania (Australia: 37.5%) [4]. The proportion of type I epithelial tumours in Hong Kong 
(51.7%) was the highest among the 51 countries, and Hong Kong was one of only two countries 
where type I epithelial tumours were more common than type II epithelial tumours. Thus, the higher 
survival for all ovarian cancers combined in Hong Kong may be partially explained by the more 
favourable distribution of histology. A favourable distribution was also seen in Ecuador, with one of 
the highest proportions of germ cell tumours (7.8%), and age-standardised 5-year survival was 
47.0% for all tumours combined [4]. 
For many areas of the world, data from population-based cancer registries are still insufficient to 
allow meaningful comparisons of ovarian cancer histology. Lack of accurate cancer registration in 
many areas, and the high proportion of non-specific morphology in many countries, still limits 
worldwide comparison of survival by histology. 
During 2005–2009, the highest proportion of tumours of non-specific morphology was seen in 
Russia (17.7%), which may explain the low proportion of type II epithelial tumours in the country, 
because many non-specific tumours will be diagnosed at an advanced stage [supplementary Table 
4]. In order to classify a tumour as a specific subtype, such as serous or endometrioid, a tissue 
biopsy or surgical resection is required; thus, histology may not be correctly classified into a 
specific subtype if the disease is diagnosed at an advanced stage. In Central and South America, the 
largest registry (Puerto Rico) provided data only for 684 women, of which 24.3% were recorded as 
having been diagnosed with undifferentiated or other epithelial carcinoma. The accuracy of 
morphology data is also reliant upon data transmission to the cancer registries and recording of 
morphology codes, so the distribution of subtypes may be affected by registry procedures and the 
classifications in use. For example, in Sweden, only 324 of 12,969 (2.5%) women with ovarian 
cancer were reported as being diagnosed with a specific morphology, compared with 6311 of 7322 
women (86.2%) in Finland. Previous reports on ovarian cancer in Sweden showed over 98% 
specific morphology codes [24]. Additionally, the distribution for Hong Kong included only 
epithelial tumours, because other ovarian cancer subtypes were not submitted. While Sweden was 
excluded from these analyses, Hong Kong was included because comparison of the most common 
groups, type I and type II epithelial, was still achievable. 
Variation between pathologists in the classification of ovarian tumours into specific histological 
subtypes may affect the distribution of subtypes within a country, and thus, comparisons of the 
distributions of subtypes between countries. Various studies conducted from 1984 to 1994 of the 
reproducibility of the World Health Organization's 1973 histological classification of ovarian 
tumours [25] showed only moderate levels of reproducibility [26]. The WHO classification for 
ovarian tumours was updated in 1999 [27], 2003 [28] and 2014 [2]. Because tumours diagnosed 
from 1995 to 2009 were included in the analysis, pathologists could have used either the 1973, 1999 
or 2003 criteria to assign a histological subtype to a tumour included in the study. The definitions of 
the various histological subtypes do not change drastically over time from 1973 to 2003, so the 
edition used by the pathologist is not necessarily relevant. However, the definitions of the subtypes 
are general and the 2003 criteria did not include changes or criteria that could improve 
reproducibility; thus, observer variation remains an issue [26]. 
Studies of immunohistochemical biomarkers and molecular genetic features for certain histological 
subtypes may allow for more reproducible diagnoses. TP53 mutations are found in 80% of women 
diagnosed with high-grade serous carcinoma, while KRAS, BRAF and ERBB2 mutations are more 
common in women with low-grade serous carcinoma. Mutations of CTNNB1, PTEN, PIK3CA are 
common in endometrioid tumours and KRAS mutations can be found in 50% of mucinous tumours. 
For clear cell carcinoma, mutations or ARID1A and PIK3CA are common [2], [6], [7], [9]. With 
this knowledge and the updated WHO classification of 2014, reproducibility of the histological 
typing of ovarian cancers should improve. 
In order to classify serous tumours appropriately into histological groups, knowledge of the tumour 
grade is important. However, data on tumour grade are not routinely collected by cancer registries. 
For ovarian cancer, most serous carcinomas are high-grade, and will have been correctly classified 
in our analysis as type II epithelial, but a small proportion are low-grade, and should have been 
classified as type I epithelial [6], [7], [9], [10], [29], [30]. Because the proportion of low-grade 
serous tumours is small [2], the effect of any misclassification on the distribution of histology is 
expected to be minimal. The distinction between high-grade and low-grade serous carcinoma is 
important, because they have a distinct pathogenesis and are thought to be different diseases [6], 
[7]. Low-grade serous carcinoma is more common in younger women, and is thought to arise from 
borderline serous tumours. In contrast, high-grade serous carcinoma is more common in older 
women, is thought to arise from tubal disease and typically exhibits p53 mutation [6], [7], [31]. 
Similarly, endometrioid tumours are classified as either low- or high-grade, and classification into 
type I or type II epithelial has previously depended on tumour grade [7]. Most endometrioid ovarian 
tumours will be low-grade [2], and some pathologists have argued that high-grade endometrioid 
tumours may not exist [7], [10]. Distinguishing between high-grade endometrioid and high-grade 
serous tumours is difficult, and when distinction between endometrioid and serous tumours is 
unclear, most high-grade tumours may be classified as high-grade serous, because this subtype is 
more common than high-grade endometrioid [7], [10]. Following an update in 2016 of the original 
definitions of type I and type II epithelial tumours, all endometrioid tumours would now be 
categorised as type I, regardless of tumour grade [6]. Future analyses of ovarian cancer survival 
should, if possible, incorporate a distinction between high- and low-grade serous carcinoma, to 
reflect the current understanding of ovarian cancer pathogenesis and behaviour, and to classify 
serous carcinomas appropriately into type I and type II epithelial tumours. 
Carcinoma, NOS (ICD-O-3 morphology code 8010), large cell carcinoma, NOS (8012) and 
adenocarcinoma, NOS (8140) were categorised as undifferentiated and other epithelial tumours and 
grouped broadly as type II epithelial. There may also be some misclassification of these tumours, 
because these morphology codes are not specific codes, so classification into type I or type II is 
difficult. However, carcinoma (NOS), large cell carcinoma (NOS) and adenocarcinoma (NOS) are 
treated clinically as if they were high-grade serous carcinomas, which are classified as type II. 
Therefore, we decided to categorise these tumours as type II epithelial. They comprise 20.9% of 
tumours included in the analysis. 
Only morphologically verified tumours, or those with specific morphologies that implied 
morphological verification, were included in the analysis. This restriction may affect the 
distribution of histological groups, because the histology of advanced-stage tumours that are not 
fully investigated may be coded as non-specific or unknown. If more advanced-stage tumours are 
not morphologically verified and therefore excluded from analysis, the distribution of histological 
groups may appear more favourable than it actually is. 
This worldwide study of ovarian cancer histology has identified striking variations in histological 
distribution, using data from population-based cancer registries in 51 countries. The two main 
histological groups of ovarian cancer have different prognosis, primarily due to differences in the 
distribution of stage, sensitivity to chemotherapy and response to surgical resection. International 
comparisons of ovarian cancer survival should take histology into account, to help identify whether 
the distribution of histology contributes to international differences in ovarian cancer survival, 
which is typically reported for all histological groups combined. To understand further the impact 
on survival, we are examining international differences in ovarian cancer survival by histological 
group. Registration of both the histology and the grade of ovarian cancers is important to help 
categorise these tumours more accurately into histological groups, especially type I and type II 
epithelial. Increased support for the development of high-quality population-based cancer registries 
in low-income countries will also help improve international comparisons of ovarian cancer 
survival. 
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